Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Platten

Showing results (291-300 of 318) with videos related to

Pageof 32
Sort By:
Nature|June 17, 2014
Aryl hydrocarbon receptor control of a disease tolerance defence pathwayAlban Bessede, Marco Gargaro, Maria T Pallotta, et al.
Nature Cancer|February 5, 2022
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomasMirco Friedrich, Roman Sankowski, Lukas Bunse, et al.
Molecular & Cellular Proteomics : MCP|June 3, 2019
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and PlasmaBracha Shraibman, Eilon Barnea, Dganit Melamed Kadosh, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Molecular & Cellular Proteomics : MCP|August 4, 2018
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and PlasmaBracha Shraibman, Eilon Barnea, Dganit Melamed Kadosh, et al.
Neuro-Oncology|December 28, 2020
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think TankPavlina Chuntova, Frances Chow, Payal B Watchmaker, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Der Nervenarzt|July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Pageof 32

Showing results (291-300 of 318) with videos related to

Sort By:
Pageof 32
Nature|June 17, 2014
Aryl hydrocarbon receptor control of a disease tolerance defence pathwayAlban Bessede, Marco Gargaro, Maria T Pallotta, et al.
Nature Cancer|February 5, 2022
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomasMirco Friedrich, Roman Sankowski, Lukas Bunse, et al.
Molecular & Cellular Proteomics : MCP|June 3, 2019
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and PlasmaBracha Shraibman, Eilon Barnea, Dganit Melamed Kadosh, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Molecular & Cellular Proteomics : MCP|August 4, 2018
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and PlasmaBracha Shraibman, Eilon Barnea, Dganit Melamed Kadosh, et al.
Neuro-Oncology|December 28, 2020
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think TankPavlina Chuntova, Frances Chow, Payal B Watchmaker, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Der Nervenarzt|July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Pageof 32